Taking stock of the drug industry, from the lab to the medicine chestMarch 29, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer Molly Ferguson for STAT STAT+ | NIH releases data showing more clinical trial sponsors are reporting results, but most miss deadlines "This is a huge step forward for clinical trial transparency," said Till Bruckner, who heads the TranspariMED advocacy group. By Ed Silverman STAT+ | Dutch health minister won't cover a Gilead cancer drug due to the cost "Inefficient spending means less money is available for other important areas of care," said Dutch health minister Ernst Kuipers. By Ed Silverman Under pressure, biotech and pharma grapple with how to take climate action The health impact of climate change: Biotech and pharma companies are under pressure to take climate action and reduce carbon emissions. By Betsy Ladyzhets JOEL SAGET/AFP via Getty Images STAT+ | British Columbia to bar Americans from buying Ozempic over supply concerns As more Americans seek out diabetes drug Ozempic to help them lose weight, British Columbia plans to limit sales to Canadian residents. By Elaine Chen New lupus partnership with FDA aims to end drug trials' history of failure With just three lupus drugs approved in six decades, the FDA will work with researchers and patients to look for better strategies. By Isabella Cueto More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments